Herpes is an infection caused by two types of viruses: herpes simplex virus (HSV) type 1 (HSV-1) and type 2 (HSV-2) that usually cause painful blisters or ulcers at the site of infection. It’s estimated that 3.7 billion people aged under 50 are infected with HSV-1, while 491.5 million people aged 15-49 are infected with HSV-2 around the world. HSV infections are lifelong and can interfere with people’s social life. Some people infected with HSV have feelings of shame and low self-esteem. The treatment options that are currently available (i.e., antivirals) cannot cure the infection.
An immunotherapy treatment (i.e., drug that activates your immune system) against genital herpes is currently being developed. This clinical trial will test if the potential study treatment is well-tolerated and could possibly decrease the number of genital herpes recurrences (i.e., reappearances of genital herpes symptoms and lesions) in this population.
If you participate in this study, you will be required to come to our clinic up to 16 times (some visits may be replaced by telephone calls) over a period of approximately 24 months. At each in-person visit you will see the study doctor and then the research team for medical assessments.
There is no cost for the study drug or study visits, and you will be compensated for time and travel.
You may qualify if:
- You are aged 18-60
- You have been diagnosed with genital herpes for at least one year
- You have had multiple outbreaks in the past year OR before you started using daily antiviral treatment (if applicable)
Further eligibility criteria apply.